Literature DB >> 25315378

Mutations in g protein encoding genes and chromosomal alterations in primary leptomeningeal melanocytic neoplasms.

Heidi V N Küsters-Vandevelde1, Ilse A C H van Engen-van Grunsven, Sarah E Coupland, Sarah L Lake, Jos Rijntjes, Rolph Pfundt, Benno Küsters, Pieter Wesseling, Willeke A M Blokx, Patricia J T A Groenen.   

Abstract

Limited data is available on the genetic features of primary leptomeningeal melanocytic neoplasms (LMNs). Similarities with uveal melanoma were recently suggested as both entities harbor oncogenic mutations in GNAQ and GNA11. Whether primary LMNs share additional genetic alterations with uveal melanoma including copy number variations is unknown. Twenty primary LMNs ranging from benign and intermediate-grade melanocytomas to melanomas were tested by direct sequencing for hotspot mutations in the genes GNA11, GNAQ, BRAF, NRAS and HRAS. Furthermore, the lesions were tested for copy number variations of chromosomes frequently present in uveal melanoma (1p, 3, 6 and 8q) by multiplex ligation-dependent probe amplification (MLPA). Genome-wide analyses of copy number alterations of two leptomeningeal melanocytic neoplasms were performed using the OncoScan SNP-array. GNAQ(Q209) mutations were present in eleven LMNs, while two of 20 cases carried a GNA11(Q209) mutation. No BRAF, HRAS or NRAS hotspot mutations were detected. Monosomy 3 and gain of 8q were present in one leptomeningeal melanoma, and one intermediate-grade melanocytoma harbored a gain of chromosome 6. With MLPA, the melanocytomas did not show any further gross chromosomal variations. Our data shows that primary LMNs, like uveal melanoma, harbor oncogenic mutations in GNAQ and GNA11 but lack mutations in BRAF, NRAS and HRAS. This finding may help in the differential diagnosis between a primary LMN and a metastasis from a cutaneous melanoma to the central nervous system. Copy number variations in some aggressive LMNs resemble those present in uveal melanoma but their prognostic significance is unclear.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25315378     DOI: 10.1007/s12253-014-9841-3

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  47 in total

1.  Melanocytic tumor with GNA11 p.Q209L mutation mimicking a foramen magnum meningioma.

Authors:  Russell G Strom; Marianna Shvartsbeyn; Marc K Rosenblum; Meera R Hameed; Khedoudja Nafa; Irina Mikolaenko; Ramesh P Babu
Journal:  Clin Neurol Neurosurg       Date:  2012-03-13       Impact factor: 1.876

2.  Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.

Authors:  Jahan S Khalili; Xiaoxing Yu; Ji Wang; Brendan C Hayes; Michael A Davies; Gregory Lizee; Bita Esmaeli; Scott E Woodman
Journal:  Clin Cancer Res       Date:  2012-06-25       Impact factor: 12.531

3.  Genomic characterization of the human heterotrimeric G protein alpha, beta, and gamma subunit genes.

Authors:  E H Hurowitz; J M Melnyk; Y J Chen; H Kouros-Mehr; M I Simon; H Shizuya
Journal:  DNA Res       Date:  2000-04-28       Impact factor: 4.458

4.  Melanoma arising in a cervical spinal nerve root: report of a case with a benign course and malignant features.

Authors:  S O Skarli; A L Wolf; D A Kristt; Y Numaguchi
Journal:  Neurosurgery       Date:  1994-03       Impact factor: 4.654

5.  Genetics of uveal melanoma and cutaneous melanoma: two of a kind?

Authors:  Thomas van den Bosch; Emine Kilic; Dion Paridaens; Annelies de Klein
Journal:  Dermatol Res Pract       Date:  2010-06-06

6.  Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.

Authors:  X Chen; Q Wu; L Tan; D Porter; M J Jager; C Emery; B C Bastian
Journal:  Oncogene       Date:  2013-10-21       Impact factor: 9.867

7.  Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.

Authors:  Erika von Euw; Mohammad Atefi; Narsis Attar; Connie Chu; Sybil Zachariah; Barry L Burgess; Stephen Mok; Charles Ng; Deborah Jl Wong; Bartosz Chmielowski; David I Lichter; Richard C Koya; Tara A McCannel; Elena Izmailova; Antoni Ribas
Journal:  Mol Cancer       Date:  2012-04-19       Impact factor: 27.401

8.  The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.

Authors:  Xinqi Wu; Meijun Zhu; Jonathan A Fletcher; Anita Giobbie-Hurder; F Stephen Hodi
Journal:  PLoS One       Date:  2012-01-12       Impact factor: 3.240

9.  Primary melanoma of the CNS in children is driven by congenital expression of oncogenic NRAS in melanocytes.

Authors:  Malin Pedersen; Heidi V N Küsters-Vandevelde; Amaya Viros; Patricia J T A Groenen; Berta Sanchez-Laorden; Jacobus H Gilhuis; Ilse A van Engen-van Grunsven; Willy Renier; Jolanda Schieving; Ion Niculescu-Duvaz; Caroline J Springer; Benno Küsters; Pieter Wesseling; Willeke A M Blokx; Richard Marais
Journal:  Cancer Discov       Date:  2013-01-09       Impact factor: 39.397

10.  High quality copy number and genotype data from FFPE samples using Molecular Inversion Probe (MIP) microarrays.

Authors:  Yuker Wang; Victoria E H Carlton; George Karlin-Neumann; Ronald Sapolsky; Li Zhang; Martin Moorhead; Zhigang C Wang; Andrea L Richardson; Robert Warren; Axel Walther; Melissa Bondy; Aysegul Sahin; Ralf Krahe; Musaffe Tuna; Patricia A Thompson; Paul T Spellman; Joe W Gray; Gordon B Mills; Malek Faham
Journal:  BMC Med Genomics       Date:  2009-02-19       Impact factor: 3.063

View more
  13 in total

1.  Activating CYSLTR2 and PLCB4 Mutations in Primary Leptomeningeal Melanocytic Tumors.

Authors:  Johannes A P van de Nes; Christian Koelsche; Marco Gessi; Inga Möller; Antje Sucker; Richard A Scolyer; Michael E Buckland; Torsten Pietsch; Rajmohan Murali; Dirk Schadendorf; Klaus G Griewank
Journal:  J Invest Dermatol       Date:  2017-05-10       Impact factor: 8.551

2.  Investigation of Somatic GNAQ, GNA11, BAP1 and SF3B1 Mutations in Ophthalmic Melanocytomas.

Authors:  Jasmine H Francis; Thomas Wiesner; Tatyana Milman; Helen H Won; Amy Lin; Vivian Lee; Daniel M Albert; Robert Folberg; Michael F Berger; Devron H Char; Brian Marr; David H Abramson
Journal:  Ocul Oncol Pathol       Date:  2016-01-27

3.  Atypical activation of the G protein Gαq by the oncogenic mutation Q209P.

Authors:  Marcin Maziarz; Anthony Leyme; Arthur Marivin; Alex Luebbers; Prachi P Patel; Zhe Chen; Stephen R Sprang; Mikel Garcia-Marcos
Journal:  J Biol Chem       Date:  2018-10-23       Impact factor: 5.157

4.  Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous system.

Authors:  Johannes van de Nes; Marco Gessi; Antje Sucker; Inga Möller; Mathias Stiller; Susanne Horn; Simone L Scholz; Carina Pischler; Nadine Stadtler; Bastian Schilling; Lisa Zimmer; Uwe Hillen; Richard A Scolyer; Michael E Buckland; Libero Lauriola; Torsten Pietsch; Andreas Waha; Dirk Schadendorf; Rajmohan Murali; Klaus G Griewank
Journal:  J Neurooncol       Date:  2016-01-07       Impact factor: 4.130

5.  Diagnosing a Primary Leptomeningeal Melanoma by Gene Mutation Signature.

Authors:  Johannes van de Nes; Karsten Wrede; Adrian Ringelstein; Mathias Stiller; Susanne Horn; Antje Sucker; Inga Möller; Simone L Scholz; Rajmohan Murali; Marco Gessi; Dirk Schadendorf; Klaus G Griewank
Journal:  J Invest Dermatol       Date:  2016-04-07       Impact factor: 8.551

Review 6.  A rare case of leptomeningeal carcinomatosis in a patient with uveal melanoma: case report and review of literature.

Authors:  Inna V Fedorenko; Brittany Evernden; Rajappa S Kenchappa; Solmaz Sahebjam; Elena Ryzhova; John Puskas; Linda McIntosh; Gisela Caceres; Anthony Magliocco; Arnold Etame; J William Harbour; Keiran S M Smalley; Peter A Forsyth
Journal:  Melanoma Res       Date:  2016-10       Impact factor: 3.599

7.  Combined Inhibition of Gαq and MEK Enhances Therapeutic Efficacy in Uveal Melanoma.

Authors:  Gabriella Bayshtok; Emilie Ceraudo; Tyler D Hitchman; Amanda R Moore; Cindy Lee; Ruobing Jia; Naitao Wang; Mohini R Pachai; Alexander N Shoushtari; Jasmine H Francis; Youxin Guan; Juliet Chen; Matthew T Chang; Barry S Taylor; Thomas P Sakmar; Thomas Huber; Ping Chi; Yu Chen
Journal:  Clin Cancer Res       Date:  2020-11-23       Impact factor: 13.801

8.  Minimal contribution of ERK1/2-MAPK signalling towards the maintenance of oncogenic GNAQQ209P-driven uveal melanomas in zebrafish.

Authors:  Mai Abdel Mouti; Christopher Dee; Sarah E Coupland; Adam F L Hurlstone
Journal:  Oncotarget       Date:  2016-06-28

9.  Gnaq and Gna11 in the Endothelin Signaling Pathway and Melanoma.

Authors:  Oscar Urtatiz; Catherine D Van Raamsdonk
Journal:  Front Genet       Date:  2016-04-20       Impact factor: 4.599

10.  SF3B1 and EIF1AX mutations occur in primary leptomeningeal melanocytic neoplasms; yet another similarity to uveal melanomas.

Authors:  Heidi V N Küsters-Vandevelde; David Creytens; Adriana C H van Engen-van Grunsven; Marcel Jeunink; Veronique Winnepenninckx; Patricia J T A Groenen; Benno Küsters; Pieter Wesseling; Willeke A M Blokx; Clemens F M Prinsen
Journal:  Acta Neuropathol Commun       Date:  2016-01-15       Impact factor: 7.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.